ATA480371A - Verfahren zur herstellung von neuen clathratverbindungen von prostaglandinen oder deren analogen mit cyclodextrin - Google Patents

Verfahren zur herstellung von neuen clathratverbindungen von prostaglandinen oder deren analogen mit cyclodextrin

Info

Publication number
ATA480371A
ATA480371A AT480371A AT480371A ATA480371A AT A480371 A ATA480371 A AT A480371A AT 480371 A AT480371 A AT 480371A AT 480371 A AT480371 A AT 480371A AT A480371 A ATA480371 A AT A480371A
Authority
AT
Austria
Prior art keywords
prostaglandines
cyclodextrin
analogs
production
clathrate compounds
Prior art date
Application number
AT480371A
Other languages
English (en)
Other versions
AT332570B (de
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of ATA480371A publication Critical patent/ATA480371A/de
Application granted granted Critical
Publication of AT332570B publication Critical patent/AT332570B/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT480371A 1970-06-10 1971-06-03 Verfahren zur herstellung von neuen clathratverbindungen von prostaglandinen oder deren analogen mit cyclodextrin AT332570B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP45050119A JPS503362B1 (de) 1970-06-10 1970-06-10

Publications (2)

Publication Number Publication Date
ATA480371A true ATA480371A (de) 1976-01-15
AT332570B AT332570B (de) 1976-10-11

Family

ID=12850213

Family Applications (1)

Application Number Title Priority Date Filing Date
AT480371A AT332570B (de) 1970-06-10 1971-06-03 Verfahren zur herstellung von neuen clathratverbindungen von prostaglandinen oder deren analogen mit cyclodextrin

Country Status (22)

Country Link
US (1) US3816393A (de)
JP (1) JPS503362B1 (de)
AT (1) AT332570B (de)
BE (1) BE768288A (de)
CA (1) CA958007A (de)
CH (1) CH568259A5 (de)
CS (1) CS170169B2 (de)
CY (1) CY895A (de)
DE (1) DE2128674C2 (de)
DK (1) DK140837B (de)
ES (1) ES392074A1 (de)
FR (1) FR2100745B1 (de)
GB (1) GB1351238A (de)
HK (1) HK17577A (de)
HU (1) HU163135B (de)
IE (1) IE35326B1 (de)
NL (1) NL162901C (de)
NO (1) NO134373C (de)
RO (1) RO62182A (de)
SE (1) SE390818B (de)
SU (1) SU404225A3 (de)
ZA (1) ZA713398B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163108A (en) * 1967-02-16 1979-07-31 Lever Brothers Company Prostaglandins
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
US3954833A (en) * 1971-04-12 1976-05-04 The Upjohn Company 16,16-Methyl and ethyl substituted PGF2.sub.α compounds
CA984387A (en) * 1971-04-12 1976-02-24 Barney J. Magerlein Analogs of prostaglandins
US3903131A (en) * 1971-04-12 1975-09-02 Upjohn Co 16 and 16,16-dimethyl PGE{HD 2{B
FR2134673A1 (en) * 1971-04-30 1972-12-08 Ono Pharmaceutical Co Novel optically active isomers of prostaglandin analoguesof natural configuration useful as hypotensive agents, diuretics,contraceptives, for treating gastric ulcer and asthma, and forinhibiting platelet aggregation
US4045467A (en) * 1972-02-18 1977-08-30 May & Baker Limited Cyclopentane derivatives
US4082789A (en) * 1972-03-28 1978-04-04 The University Court Of The University Of Edinburgh Prostaglandins C2
JPS4926258A (de) * 1972-07-06 1974-03-08
US4110368A (en) * 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US4130721A (en) * 1972-07-24 1978-12-19 The Upjohn Company 11-Deoxy PGE2 compounds
US4141914A (en) * 1972-07-24 1979-02-27 American Cyanamid Company Novel 11-deoxy-11-substituted prostaglandins of the E and F series
JPS4942648A (de) * 1972-08-24 1974-04-22
US3962312A (en) * 1972-09-21 1976-06-08 Ono Pharmaceutical Company 9,11,15-Trihydroxy prost-5-enoic acid analogues
US3972917A (en) * 1972-10-27 1976-08-03 American Home Products Corporation 11-Deoxy 15-methyl prostaglandin E1
JPS5443570B2 (de) * 1972-10-27 1979-12-20
US4092427A (en) * 1973-04-16 1978-05-30 American Home Products Corporation Method of inducing abortion using alkyl derivatives of prostanoic acids
JPS5623984B2 (de) * 1973-04-19 1981-06-03
US4246426A (en) * 1973-08-06 1981-01-20 Hoffmann-La Roche Inc. 11-Substituted prostaglandins
US4059576A (en) * 1973-08-06 1977-11-22 Hoffmann-La Roche, Inc. 11-Substituted prostaglandins
US4052446A (en) * 1973-08-06 1977-10-04 Hoffmann-La Roche Inc. 11,16-substituted prostaglandins
US4026927A (en) * 1973-09-25 1977-05-31 Yamanouchi Pharmaceutical Co., Ltd. Novel prostaglandin derivatives
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
GB1448268A (en) * 1973-11-13 1976-09-02 May & Baker Ltd Cyclopentane derivatives
GB1441564A (en) * 1974-02-07 1976-07-07 Upjohn Co Prostaglandins
US4041066A (en) * 1974-02-07 1977-08-09 The Upjohn Company 4,5-Cis-didehydro-PGE1 compounds
DE2416193C2 (de) * 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
US4256651A (en) * 1974-10-02 1981-03-17 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF1β compounds
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
GB1482010A (en) * 1974-10-28 1977-08-03 Ono Pharmaceutical Co Prostaglandin analogues
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4207420A (en) * 1975-02-24 1980-06-10 The Upjohn Company 2,2-Difluoro-PGF1 analogs
US4209637A (en) * 1975-02-24 1980-06-24 The Upjohn Company 2,2-Difluoro-PGF2 analogs
US4059701A (en) * 1975-04-17 1977-11-22 American Home Products Corporation 15-Substituted prostanoic acids for treating bronchial spasm
FR2313019A2 (fr) * 1975-06-04 1976-12-31 Ono Pharmaceutical Co Nouveaux analogues de prostaglandines et leur procede de preparation
US4086269A (en) * 1975-07-07 1978-04-25 American Home Products Corporation 11-Deoxy-15-substituted prostaglandins
US4026909A (en) * 1975-07-14 1977-05-31 The Upjohn Company Cis-13-PGF2.sub.α analogs
US4016184A (en) * 1975-09-17 1977-04-05 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD1 compounds
US4033989A (en) * 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4013695A (en) * 1975-10-02 1977-03-22 The Upjohn Company 4,4,5,5-Tetradehydro-PGE1 analogs
US4053500A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGF1α analogs
US4053502A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGE1 analogs
US4026919A (en) * 1975-10-23 1977-05-31 The Upjohn Company PGD2 Substituted esters
US4058665A (en) * 1975-11-06 1977-11-15 Yamanouchi Pharmaceutical Co., Ltd. Novel 3,15-dilower alkyl PGE2 derivatives
US4212987A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4212986A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE2 analogs
US4169895A (en) * 1976-09-28 1979-10-02 Pfizer Inc. Antisecretory 16,16-dimethyl-17-oxaprostaglandins
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
HU179141B (de) * 1977-09-23 1982-08-28
JPS5577440U (de) * 1978-11-25 1980-05-28
US4244883A (en) * 1979-09-12 1981-01-13 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF2β compounds
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
US5221695A (en) * 1987-12-22 1993-06-22 Glaxo Group Limited Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
KR890009402A (ko) * 1987-12-22 1989-08-01 베리 에이.뉴샘 피페리디닐시클로펜틸헵텐산 유도체를 함유한 수용성 제제
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DE19828881A1 (de) * 1998-06-22 1999-12-23 Schering Ag Oxidationsinhibitor bei Prostan-Derivaten
US6287603B1 (en) 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
EP1417975B1 (de) 2001-07-23 2011-03-02 Ono Pharmaceutical Co., Ltd. Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
JP4497320B2 (ja) 2002-10-10 2010-07-07 小野薬品工業株式会社 内因性修復因子産生促進剤
JP4666257B2 (ja) 2003-07-25 2011-04-06 小野薬品工業株式会社 軟骨関連疾患治療剤
CN100542537C (zh) * 2004-07-27 2009-09-23 中国人民解放军军事医学科学院毒物药物研究所 ***素e1口腔制剂
WO2006137959A1 (en) * 2005-06-13 2006-12-28 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
KR20080023684A (ko) * 2005-06-13 2008-03-14 카아길, 인코포레이팃드 시클로덱스트린 포접 착물 및 이의 제조 방법
EP2027136A4 (de) * 2006-06-13 2011-08-03 Cargill Inc Grossteilige cyclodextrin-einschlusskomplexe und verfahren zu deren herstellung
JP2010514794A (ja) * 2006-12-27 2010-05-06 カーギル インコーポレイテッド シクロデキストリン封入複合体および該複合体を調製する方法
BRPI0807942A2 (pt) 2007-02-16 2014-07-01 Ono Pharmaceutical Co Agente terapêutico para distúrbio de excreção urinária
CA2684922A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic t cell activator comprising ep4 agonist
US20080283693A1 (en) * 2007-05-15 2008-11-20 Evans Michael J F Propulsion apparatus and system
PL2441760T3 (pl) 2009-06-10 2014-05-30 Ono Pharmaceutical Co Związek o działaniu kurczącym mięsień-wypieracz i zwiotczającym mięsień-zwieracz cewki moczowej
JP4890657B1 (ja) * 2011-06-03 2012-03-07 小野薬品工業株式会社 リマプロストとβ−シクロデキストリンを含有する錠剤
JP6052175B2 (ja) 2011-08-02 2016-12-27 小野薬品工業株式会社 左室拡張機能改善剤
CA2882732C (en) 2012-08-31 2021-03-30 Ono Pharmaceutical Co., Ltd. A 2-[(2-{(1r,5r)-2-oxo-5-[(1e,4s)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadiene-1-yl]cyclopentyl}ethyl)thio}-1,3-thiazole-4-carboxylic acid 4-piperidinemethanol salt and crystals thereof
PT3456710T (pt) 2016-05-09 2021-09-02 Agc Inc Novo derivado de prostaglandina
EP4403542A1 (de) * 2021-09-13 2024-07-24 FUJIFILM Corporation Herstellungsverfahren zur verkapselung einer bicycloalkanverbindung

Also Published As

Publication number Publication date
DE2128674C2 (de) 1982-06-24
ES392074A1 (es) 1974-08-01
HU163135B (de) 1973-06-28
US3816393A (en) 1974-06-11
DE2128674A1 (de) 1971-12-16
NL162901C (nl) 1980-07-15
SU404225A3 (de) 1973-10-26
NO134373C (de) 1976-09-29
CS170169B2 (de) 1976-08-27
RO62182A (de) 1977-07-15
HK17577A (en) 1977-04-22
DK140837C (de) 1981-09-07
DK140837B (da) 1979-11-26
CH568259A5 (de) 1975-10-31
NO134373B (de) 1976-06-21
CA958007A (en) 1974-11-19
NL7107894A (de) 1971-12-14
IE35326L (en) 1971-12-10
IE35326B1 (en) 1976-01-07
GB1351238A (en) 1974-04-24
SE390818B (sv) 1977-01-24
BE768288A (fr) 1971-11-03
FR2100745A1 (de) 1972-03-24
JPS503362B1 (de) 1975-02-04
NL162901B (nl) 1980-02-15
FR2100745B1 (de) 1974-08-30
AT332570B (de) 1976-10-11
ZA713398B (en) 1972-01-26
CY895A (en) 1977-10-07

Similar Documents

Publication Publication Date Title
AT332570B (de) Verfahren zur herstellung von neuen clathratverbindungen von prostaglandinen oder deren analogen mit cyclodextrin
AT315838B (de) Verfahren zur Herstellung von neuen 8-Azapurin-6-on-derivaten
AT311557B (de) Verfahren zur Herstellung von neuen α-Aminopenicillinen
AT314826B (de) Verfahren zur Herstellung von modifizierten Erdölharzen
AT317536B (de) Verfahren zur Herstellung von Kohlenwasserstoffharzen
AT323902B (de) Verfahren zur herstellung von neuen thio-pyrimidin-derivaten
AT307619B (de) Verfahren zur Herstellung von Penicillinsulfoxyden
CH550133A (de) Verfahren zur herstellung von 4-methyl-pentanol-2-crotonat.
AT310148B (de) Verfahren zur Herstellung von neuen Norpinanderivaten
AT308075B (de) Verfahren zur Herstellung von Monochlorbenzaldehyden
AT310769B (de) Verfahren zur Herstellung von ɛ-Caprolacton
CH529128A (de) Verfahren zur Herstellung von Tetronsäure
AT311930B (de) Verfahren zur herstellung von isopren
CH550214A (de) Verfahren zur herstellung von cyclocopolymerisaten.
AT307418B (de) Verfahren zur Herstellung von neuem 8-Cyano-5-octanolid
AT324546B (de) Verfahren zur herstellung von aminopenicillinen
AT309683B (de) Verfahren zur Herstellung von neuen Penicillinen
CH558800A (de) Verfahren zur herstellung von chinazolinonen.
CH547775A (de) Verfahren zur herstellung von diaethylaminopropionaniliden.
AT314096B (de) Verfahren zur Herstellung von substituierten Cobamiden
CH555314A (de) Verfahren zur herstellung von cyclopropylmethylalkylaminen.
AT310958B (de) Verfahren zur Herstellung von neuen Octadecapeptiden
AT309705B (de) Verfahren zur Herstellung von neuen 21-Floursteroiden
AT312583B (de) Verfahren zur Herstellung von Isothymol
CH540230A (de) Verfahren zur Herstellung von Phenäthylamiden

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee